AKRO News and Press, Akero Therapeutics Inc. From 11/04/22

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter fina...

Summary Akero recently presented data which did not follow an intent-to-treat (ITT) analysis. They admitted this would have made them miss at least one endpoint. The company twice now has not let investors see all the data from its clinical studies. There are other issues with...

Summary 88% technical buy signals. 7 new highs and up 222.89% in the last month. Analyst's price targets from 30.00 to 62.00. The Chart of the Day belongs to the health care company Akero Therapeutics ( AKRO ). I found the stock by sorting the Russell 3000 In...

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that managem...

Summary Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach. Biotechs benefit if a...

Akero Therapeutics ( NASDAQ: AKRO ) has announced the closing of its previously announced upsized public offering of ~8.85M shares of its common stock at a public offering price of $26/share taking gross proceeds to ~$230M. Also, includes the exercised full by the und...

Summary Despite the recent resurgence, many biotech innovators are still trading at a fraction of their intrinsic value. In studying the biotech landscape, I recently uncovered another promising innovator dubbed Akero Therapeutics. With the recent robust Phase 2b data, Akero i...

Summary Akero Therapeutics recently posted solid phase 2b data. Akero appears adequately funded. Akero Therapeutics will begin a phase 3 trial after this. Akero Therapeutics, Inc. ( AKRO ), which I have been accumulating on dips over the last 1.5 years, has had a...

Summary Altimmune stock was trading lower after the release of positive results, achieving both primary and secondary endpoints of phase 1b study with pemvidutide in NASH/obese patients provides a buying opportunity. It provided updated 24-week results from phase 1b study using pe...

Akero Therapeutics ( NASDAQ: AKRO ) shares are down 2.53% after-hours after the firm prices an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00/share for expected gross proceeds to be ~$200.0M. All of the...